Endocrine Abstracts

Context: There is scant evidence of tumoral mass reduction in Thyrotropin-secreting pituitary adenomas (TSPA) treated with long-acting somatostatin analogs. There are no reports that evaluate TSPA shrinkage after deep subcutaneous (sc) Lanreotide-ATG (L-ATG) therapy.Objective: The primary objective was to observe if L-ATG could reduce TSPA tumor mass.Methods: A literature review on the subject was made. The biochemical and radiolog...